Axogen (AXGN) Cash from Financing Activities (2010 - 2026)
Axogen (AXGN) recorded quarterly Cash from Financing Activities of $59.5 million in Q1 2026, up 1203.22% quarter-over-quarter from $4.6 million in Q4 2025, and up 2398.11% on a YoY basis from $2.4 million in Q1 2025.
Axogen (AXGN) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Axogen's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $59.5 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 2398.11% year-over-year to $59.5 million; the TTM figure through Mar 2026 stood at $67.6 million (up 1413.47% YoY), while the FY2025 annual figure was $10.5 million, up 358.47% from the prior year.
- Cash from Financing Activities was $59.5 million for Q1 2026 at Axogen, up from $4.6 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $59.5 million in Q1 2026 to a low of $5000.0 in Q3 2023.
- Historically, Cash from Financing Activities has averaged $4.5 million across 5 years, with a median of $671000.0 in 2022.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities slumped 97.67% in 2023, then surged 11340.0% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at $813000.0 in 2022, then sank by 48.59% to $418000.0 in 2023, then soared by 132.06% to $970000.0 in 2024, then jumped by 370.72% to $4.6 million in 2025, then soared by 1203.22% to $59.5 million in 2026.
- The last three Cash from Financing Activities figures came in at $59.5 million (Q1 2026), $4.6 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | -2.09 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -26.93 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | -25.00 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | -97.90 Mn |
| 10 | Axogen | 2.32 Bn | 2.22 Bn | 46.19 Mn | 59.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.51 Mn |
| Mar 31, 2026 | 59.51 Mn |
| Dec 31, 2025 | 4.57 Mn |
| Dec 31, 2025 | 4.57 Mn |
| Sep 30, 2025 | 2.39 Mn |
| Sep 30, 2025 | 2.39 Mn |
| Jun 30, 2025 | 1.16 Mn |
| Jun 30, 2025 | 1.16 Mn |
| Mar 31, 2025 | 2.38 Mn |
| Mar 31, 2025 | 2.38 Mn |
| Dec 31, 2024 | 970,000.00 |
| Dec 31, 2024 | 970,000.00 |
| Sep 30, 2024 | 572,000.00 |
| Sep 30, 2024 | 572,000.00 |
| Jun 30, 2024 | 544,000.00 |
| Jun 30, 2024 | 544,000.00 |
| Mar 31, 2024 | 204,000.00 |
| Mar 31, 2024 | 204,000.00 |
| Dec 31, 2023 | 418,000.00 |
| Dec 31, 2023 | 418,000.00 |